Bright Minds Biosciences INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Cormorant Asset Management, LP and Bihua Chen have reported an increase in their beneficial ownership of Bright Minds Biosciences Inc. common shares to 9.17%.
NASDAQ
Adage Capital Management, L.P. and its principals have filed a Schedule 13G, reporting beneficial ownership of 3.41% of Bright Minds Biosciences Inc. common shares.
NASDAQ
Vestal Point Capital, LP and Ryan Wilder have filed a Schedule 13G reporting a 5% beneficial ownership stake in Bright Minds Biosciences Inc.
NASDAQ
Janus Henderson Group plc has filed a Schedule 13G, reporting beneficial ownership of 13.1% of Bright Minds Biosciences Inc. common stock as of March 31, 2026.
NASDAQ
Janus Henderson Group plc has filed a Schedule 13G, reporting beneficial ownership of 13.1% of Bright Minds Biosciences Inc. common stock as of March 31, 2026.
NASDAQ
Vivo Opportunity Fund Holdings, L.P. has filed a Schedule 13G reporting a 5.2% beneficial ownership stake in Bright Minds Biosciences Inc.
NASDAQ
Cormorant Asset Management and Bihua Chen have reported a 9.71% beneficial ownership stake in Bright Minds Biosciences Inc.
NASDAQ
Cormorant Asset Management and Bihua Chen report a 10.88% beneficial ownership stake in Bright Minds Biosciences Inc. common shares.
NASDAQ
Vivo Opportunity Fund Holdings, L.P. and its affiliates have reported a 6.4% beneficial ownership stake in Bright Minds Biosciences Inc. as of September 30, 2025.
NASDAQ
Adage Capital Management, L.P. and its principals have disclosed a 5.58% beneficial ownership stake in Bright Minds Biosciences Inc. as of September 30, 2025.
NASDAQ
Sio Capital Management, LLC has filed an amended Schedule 13G, reporting a 2.69% beneficial ownership stake in Bright Minds Biosciences Inc. as of September 30, 2025.
NASDAQ
Janus Henderson Group plc and its affiliate reported a significant beneficial ownership stake in Bright Minds Biosciences Inc., totaling 16.3% of common stock.
NASDAQ
Sio Capital Management, LLC reports a 7.27% passive stake in Bright Minds Biosciences Inc., holding 512,338 common shares.
NASDAQ
RA Capital Management, L.P. and its affiliates have filed an amended Schedule 13G, disclosing a reduction in their beneficial ownership of Bright Minds Biosciences Inc. common shares to 2.9%.
NASDAQ
SCHEDULE 13G/A: Perceptive Advisors and Joseph Edelman Disclose 6.3% Stake in Bright Minds Biosciences
Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have jointly reported a 6.3% beneficial ownership stake in Bright Minds Biosciences Inc., holding 444,649 common shares.
NASDAQ
Sio Capital Management, LLC has reported a 7.21% beneficial ownership stake in Bright Minds Biosciences Inc., holding 507,562 common shares as of March 31, 2025.
NASDAQ
Janus Henderson Group plc, through its affiliates, has disclosed a beneficial ownership of 16.0% in Bright Minds Biosciences Inc.'s common stock as of March 31, 2025, according to an amended Schedule 13G filing.
NASDAQ
SCHEDULE 13G/A: Point72 Asset Management Reduces Stake in Bright Minds Biosciences Below 5% Threshold
Point72 Asset Management, along with its affiliates and Steven A. Cohen, has reported a reduction in its beneficial ownership of Bright Minds Biosciences Inc. common shares to 3.0% as of December 31, 2024.
NASDAQ
Commodore Capital LP and Commodore Capital Master LP have reported a passive beneficial ownership of 7.2% in Bright Minds Biosciences Inc., totaling 500,000 common shares as of December 31, 2024.
NASDAQ
Sio Capital Management, LLC has reported a passive beneficial ownership of 6.50% of Bright Minds Biosciences Inc.'s common shares as of December 31, 2024.
NASDAQ
Janus Henderson Group PLC and its affiliate, Janus Henderson Biotech Innovation Master Fund Ltd, have reported beneficial ownership of 11.6% of Bright Minds Biosciences Inc.'s common stock.